Edmond DE Rothschild Holding S.A. Takes Position in Ionis Pharmaceuticals, Inc. $IONS

Key Points

• Edmond DE Rothschild Holding S.A. has acquired 124,200 shares of Ionis Pharmaceuticals valued at approximately $3.75 million, representing about 0.08% of the company.
• Ionis Pharmaceuticals reported an impressive 100.9% increase in revenue year-over-year, reaching $452 million for the last quarter, and beat earnings estimates by $0.51 with $0.70 per share.
• Several brokerages have increased their target prices for Ionis Pharmaceuticals, with HC Wainwright raising its target from $70 to $95, reflecting a strong analyst consensus rating of "Moderate Buy."

Edmond DE Rothschild Holding S.A. acquired a new stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 124,200 shares of the company's stock, valued at approximately $3,747,000. Edmond DE Rothschild Holding S.A. owned about 0.08% of Ionis Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently modified their holdings of the company. Signaturefd LLC lifted its position in shares of Ionis Pharmaceuticals by 45.6% during the 1st quarter. Signaturefd LLC now owns 1,382 shares of the company's stock valued at $42,000 after acquiring an additional 433 shares during the last quarter. Ancora Advisors LLC purchased a new stake in shares of Ionis Pharmaceuticals in the first quarter valued at $60,000. Raiffeisen Bank International AG purchased a new stake in shares of Ionis Pharmaceuticals in the fourth quarter valued at $62,000. CWM LLC boosted its position in shares of Ionis Pharmaceuticals by 18.7% in the first quarter. CWM LLC now owns 2,435 shares of the company's stock worth $73,000 after buying an additional 384 shares during the period. Finally, Exchange Traded Concepts LLC boosted its position in shares of Ionis Pharmaceuticals by 1,722.5% in the first quarter. Exchange Traded Concepts LLC now owns 3,244 shares of the company's stock worth $98,000 after buying an additional 3,066 shares during the period. Institutional investors and hedge funds own 93.86% of the company's stock.

Ionis Pharmaceuticals Price Performance

Shares of NASDAQ:IONS opened at $59.35 on Friday. The company has a current ratio of 2.87, a quick ratio of 2.86 and a debt-to-equity ratio of 0.99. Ionis Pharmaceuticals, Inc. has a 1 year low of $23.95 and a 1 year high of $62.08. The business has a fifty day simple moving average of $43.22 and a 200 day simple moving average of $36.14. The firm has a market cap of $9.46 billion, a price-to-earnings ratio of -32.26 and a beta of 0.28.

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.70 earnings per share for the quarter, beating analysts' consensus estimates of $0.19 by $0.51. The business had revenue of $452.00 million for the quarter, compared to the consensus estimate of $270.90 million. Ionis Pharmaceuticals had a negative net margin of 28.25% and a negative return on equity of 45.29%. Ionis Pharmaceuticals's revenue for the quarter was up 100.9% on a year-over-year basis. During the same quarter last year, the firm earned ($0.45) EPS. Ionis Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently commented on IONS. HC Wainwright raised their target price on Ionis Pharmaceuticals from $70.00 to $95.00 and gave the stock a "buy" rating in a research report on Tuesday. Wells Fargo & Company raised their target price on Ionis Pharmaceuticals from $77.00 to $82.00 and gave the stock an "overweight" rating in a research report on Friday, August 22nd. Stifel Nicolaus set a $43.00 target price on Ionis Pharmaceuticals in a research report on Thursday, August 21st. Royal Bank Of Canada raised their target price on Ionis Pharmaceuticals from $70.00 to $80.00 and gave the stock an "outperform" rating in a research report on Thursday. Finally, Needham & Company LLC raised their target price on Ionis Pharmaceuticals from $55.00 to $70.00 and gave the stock a "buy" rating in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $67.88.

Insider Activity

In other Ionis Pharmaceuticals news, EVP Eugene Schneider sold 19,658 shares of the stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $60.81, for a total transaction of $1,195,402.98. Following the transaction, the executive vice president directly owned 51,507 shares of the company's stock, valued at $3,132,140.67. This represents a 27.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director B Lynne Parshall sold 20,000 shares of the stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $50.91, for a total transaction of $1,018,200.00. Following the transaction, the director directly owned 66,344 shares in the company, valued at $3,377,573.04. The trade was a 23.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 464,141 shares of company stock valued at $26,772,779. Corporate insiders own 2.60% of the company's stock.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.